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Abstract 
Neuroblastoma (NB) is a frequent embryonal tumour of sympathetic ganglia and 
adrenals with extremely variable outcome. Recently, somatic amplification and gain-of-
function mutations of the anaplastic lymphoma receptor tyrosine kinase (ALK, MIM 105590) 
gene, either somatic or germline, were identified in a significant proportion of NB cases.  
Here we report a novel syndromic presentation associating congenital NB with severe 
encephalopathy and abnormal shape of the brainstem on brain MRI in two unrelated sporadic 
cases harbouring de novo, germline, heterozygous ALK gene mutations. Both mutations are 
gain-of-function mutations that have been reported in NB and NB cell lines. These 
observations further illustrate the role of oncogenes in both tumour predisposition and normal 
development, and shed light on the pleiotropic and activity-dependent role of ALK in 
humans. More generally, missing germline mutations relative to the spectrum of somatic 
mutations reported for a given oncogene may be a reflection of severe effects during 
embryonic development, and may prompt mutation screening in patients with extreme 
phenotypes.  
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Introduction 
Neuroblastoma (NB; MIM 256700) is the most frequent extra-cranial solid tumour in 
children. Both familial cases with vertical transmission, and predisposition in chromosomal 
and monogenic syndromes, have long supported the involvement of genetic factors. Several 
NB predisposing genes were recently identified, such as PHOX2B, CREBBP, NSD1, HRAS, 
NF1 and ALK. The last three genes encode proteins involved in the RAS/MAPK pathway 
[Chiarle, et al., 2008; Palmer, et al., 2009] and ALK is a downstream target of PHOX2B 
[Bachetti, et al., 2010].  
ALK, a tyrosine kinase receptor gene of the insulin receptor family, is activated by 
fusion with various partners in anaplastic large cell lymphomas, inflammatory 
myofibroblastic tumours and in some lung cancers [Chiarle, et al., 2008]. Recently, somatic 
amplification and gain-of-function mutations of ALK were identified in about 2-4 and 7-10% 
of NB cases respectively [Chen, et al., 2008; Janoueix-Lerosey, et al., 2008; Mosse, et al., 
2008; De Brouwer, et al., 2010]. Germline gain-of-function mutations have also been reported 
in half of the familial cases of NB tested thus far [Janoueix-Lerosey, et al., 2008; Mosse, et 
al., 2008]. ALK is preferentially expressed in the central and peripheral nervous systems 
during development but its role in the normal development of the nervous system remains 
speculative [Iwahara, et al., 1997; Vernersson, et al., 2006; Hurley, et al., 2006]. Indeed, 
familial ALK gain-of-function mutations predispose to isolated NB, but are not associated 
with developmental anomalies, and Alk-/- mice have no obvious embryonic phenotype. 
However, behavioural impairment has been described in the Alk-/- mice, a phenotype 
attributed to neurochemical alterations in the hippocampi and basal cortex [Bilsland, et al., 
2008]. 
Here we report two unrelated cases with an association of congenital NB and severe 
encephalopathy characterised by a specific abnormal shape of the brainstem on brain 
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magnetic resonance imaging (MRI). In both cases we identified a heterozygous, germline de 
novo missense mutation located in the tyrosine kinase domain (TKD) of ALK at positions 
previously identified as somatic mutational hot-spots in NB and NB cell lines. 
 
 
Patients and Methods  
Case1, a female, was the second child born to unrelated healthy parents, aged 29 and 
31 years at the time of birth, with no relevant family medical history. She was born at term by 
caesarean section with normal birth parameters following an uneventful pregnancy (BW : 
3100 g, BL : 46 cm, OFC : 34 cm). She was hypotonic, hypomotile and presented with major 
feeding difficulties, no sucking and swallowing reflexes, episodes of abdominal distension 
and apneas. Mechanical ventilation and tube feeding were required. An adrenal NB with 
pelvic extension was diagnosed at three days of life. Levels of urinary catecholamine and its 
metabolites were raised. Rapid tumour progression led to chemotherapy by vincristine and 
cyclophosphamide with no improvement of the tumour mass or catecholamine excretion. Boli 
of corticosteroids were delivered and plasmapheresis performed with the hypothesis of a 
paraneoplasic syndrome, but no neurological improvement was seen.  
There was no congenital malformation or morphologic abnormality at clinical 
examination except for a high arched palate. Neurologic development was poor. She could fix 
and follow with normal eye movements and remained hypotonic with little spontaneous 
movements, sucking and swallowing were absent, she experienced severe episodes of 
desaturation and sweating and she displayed hyperextension of the limbs. A tracheostomy 
tube was inserted at six weeks of age. Osteotendinous reflexes were present. A deceleration of 
the head circumference’s growth was noticeable with OFC of 39 cm (5th centile) at four 
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months. She died at age four and a half months from a severe apnea with no attempt at 
resuscitation. Necropsy was not performed. 
The tumour was classified as stage 3 by histology [Brodeur, et al., 1993]. Neither 
MYCN amplification nor 1p36 deletion were detected by FISH. No antineuronal antibodies 
were secreted in the CSF. A computerised tomography (CT) scan showed no spinal cord 
compression. Meta-iodo-benzyl-guanidine (MIBG) scintiscan showed no bone fixation. 
Electromyography and muscle histology were within the normal limits. 
Electroencephalography (EEG) showed slow activity without epilepsy. Auditory evoked 
potential was normal. Histological examination of a rectal biopsy showed normal enteric 
plexuses eliminating Hirschsprung disease as the cause of abdominal distension.  Blood 
karyotype and a comparative genomic hybridization (CGH)-array with a 650 kb resolution 
showed normal chromosomes 46, XX. Brain magnetic resonance imaging (MRI) was 
performed at three days and again at 15 weeks of age. At the latter time point, an abnormal 
shape of the brainstem was noted with an enlarged medulla oblongata eclipsing the ovoid 
form of the pons. In retrospect, the same image was present from birth (Figure 1A).  
 
Case 2, a female, was the first child born to unrelated healthy parents with no relevant 
family medical history. Intra-uterine growth retardation and sinusoidal cardiotocograph led to 
emergency Caesarean section at 31 weeks gestation (BW 1300 g, and a head circumference of 
28.5 cm; both at approximately the 25th centile). Paternal and maternal ages at time of birth 
were 42 and 37 years respectively. Hypotonia with little spontaneous movements, poor 
sucking, gastro-oesophageal reflux and distended abdomen were noted at birth. She presented 
daily episodes of desaturation and tracheobronchomalacia necessitating respiratory support 
and a tracheostomy tube was inserted at age three months. A thoraco-abdominal CT scan at 
age three weeks showed bilateral large heterogeneous and calcified adrenal masses. She 
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underwent four courses of chemotherapy leading to a reduction in the size of the tumours, but 
a MIBG scintiscan showed uptake of dye in the right hemithorax that was later confirmed by 
CT scan. She had a patent foramen ovale with prolonged QT segments on 
electrocardiography. Bilateral hernias were surgically repaired at age two months. She was 
kept on nasogastric feeds for persistent difficulties in swallowing. Intermittent abdominal 
distension remained unexplained; a contrast enema showed no obstruction and endoscopic 
intestinal biopsies were normal. Temperature instability was also observed. At age five 
months, she developed abnormal movements of the right arm and leg. Repeated EEGs failed 
to show focal epileptiform activity and seizures arising from the brainstem were hypothesised. 
Although initially normal, cranial ultrasound showed an ischaemic cortical lesion on the right 
inferior parietal lobe. Growth parameters had all fallen below the 0.4th centile by age five 
months. At nine months, she could fix, had a left convergent squint with normal fundi and 
responded to sound. Sensory motor deficit was suspected. She died at age nine months 
following a decision to withdraw intensive care. Necropsy was not performed.  
In retrospect, the brain MRIs performed at age six and 15 weeks showed a brainstem 
shape very similar to that observed in case 1 (Figure 1B). At histology, both adrenal biopsies 
showed infiltrating islands of undifferentiated neuroblasts. FISH analysis identified four 
copies of the MYCN gene, trisomy of chromosomes 1 and 9 and tetrasomy of chromosome 17.  
Blood samples for both cases were obtained with informed consent and DNA was 
extracted according to standard protocols. Direct sequencing of the ALK and PHOX2B genes 
was performed on both strands as previously described using the Big Dye Terminator Cycle 
Sequencing kit (Applied Biosystems) and was analyzed on an ABI 3100 automated 
sequencer.  
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Results  
No nucleotidic variation of the PHOX2B gene was found. A heterozygous variation of 
the ALK gene was identified in each case (c.3733T>G, p.F1245V in case 1 and c.3520T>G, 
p.F1174V in case 2; numbering is based on the cDNA sequence from NM_004304.3 
(ALK_v001), Figure 2). Each missense mutation altered a conserved amino acid within the 
intracellular TKD of the protein at a position already found mutated in several NB cell lines 
and tumours (reviewed in [Palmer, et al., 2009] and [Janoueix-Lerosey, et al., 2010]). Both 
mutations occurred de novo. A paternal contribution to the child genotype was confirmed for 
nine unlinked and polymorphic CA repeat microsatellite markers in case 1 and 2 (data 
available on request).  
 
 
Discussion  
 
In both cases described in this report, we identified a de novo heterozygous germline 
ALK gene mutation. Importantly, mutations at position p.F1174 and p.F1245 have been 
reported already (with substitution for I, C, V and L amino acids in both cases), but were 
invariably somatic [De Brouwer, et al., 2010; Janoueix-Lerosey, et al., 2010; Palmer, et al., 
2009]. However, the missense mutations p.G1128A, p.R1192P and p.R1275Q, lying in the 
TKD of ALK, have been reported in familial cases segregating NB predisposition with 
incomplete penetrance and without presenting any neurological symptoms, and have not been 
reported as somatic mutations [Janoueix-Lerosey, et al., 2008; Mosse, et al., 2008]. 
Conversely, both children reported here presented with multifocal NB of neonatal onset and, 
severe, non epileptic encephalopathy with a fatal outcome. They were initially referred for 
possible central congenital hypoventilation syndrome (CCHS, Ondine’s curse MIM209880) 
due to episodes of apnoeas and desaturation, abdominal distension and NB. However, these 
episodes were independent of the sleep-wake state and direct sequencing of the PHOX2B 
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gene failed to identify a coding sequence mutation. Opsomyoclonic syndrome had also been 
considered but electroencephalographic recordings showed no epilepsy and eye movements 
were normal. Moreover, plasmapheresis and corticosteroids did not lead to neurological 
improvement. Compression by the abdominal mass and Hirschsprung disease were also 
considered as explanations for the episodes of abdominal distension. An alternative 
hypothesis is enteric nervous system dysfunction given that Alk is expressed in the developing 
gut in mice [Vernersson, et al., 2006]. The brainstem anomaly in the two patients reported 
here does not seem progressive, although this could not be assessed fully, given that both 
patients died at an early age. Nonetheless, the medulla oblongata was enlarged from birth in 
both cases. The presence of this feature upon brain MRI may be a good indication of an ALK 
germline mutation in a newborn with severe encephalopathy and brainstem dysfunction of 
unknown cause with or without NB. Indeed, whether neonatal NB is a consistent feature of 
the syndrome remains to be defined. The differential diagnosis would be a tumour of the 
medulla (more often a pylocytic astrocytoma), but enlargement would be asymmetric and 
presenting hypointensity on T1-weighted images.  
There is a sharp contrast between the brain phenotype of the patients described in this 
report, and that of patients with Cardio-Facio-Cutaneous syndromes, in which germline gain-
of-function mutations in several genes involved in the RAS signalling pathway have been 
described, and for whom absolute or relative macrocephaly is the rule (see [Tidyman and 
Rauen, 2009] for review). This is particularly true for Costello syndrome, which is ascribed to 
HRAS gain-of-function mutations, with amino acid substitution hotspots at codons p.G12 and 
p.G13 [Aoki, et al., 2005]. Interestingly, a progressive enlargement of the cerebellum leading 
to posterior fossa crowding and cerebellar tonsilar herniation has been described in a majority 
of patients with Costello syndrome, while the shape of the brainstem remains normal [Gripp, 
et al., 2010].  
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ALK is an extremely conserved tyrosine kinase receptor of the insulin receptor family 
with Midkine and Pleiotrophin as putative ligands in mammals. Ligand binding leads to ALK 
heterodimerisation, autophosphorylation and activation of the RAS/MAPK, phosphoinositide-
3 kinase (PI3K)/AKT, JAK/STAT3 or PLCγ pathways, promoting proliferation, 
differentiation or survival [Chiarle, et al., 2008; Palmer, et al., 2009; Wasik, et al., 2009]. 
Fusion proteins arising from somatic rearrangements have been reported in anaplastic large 
cell lymphomas and other tumours (reviewed in [Palmer, et al., 2009]). In NB and NB cell 
lines, both ALK amplification and gain-of-function missense mutations of conserved codons 
of the TKD have been reported [Chen, et al., 2008; George, et al., 2008; Janoueix-Lerosey, et 
al., 2008; Passoni, et al., 2009]. Some experimental data indicate variable oncogenic potential 
of ALK mutants with p.F1174L having an increased transforming capacity compared to 
p.R1275Q and p.K1062M [Chen, et al., 2008; De Brouwer, et al., 2010]. Altogether, these 
observations suggest different effects on ALK signalling for different mutations, with variable 
biological consequences. An interesting possibility is that there is an ALK activity threshold, 
above which CNS development would be impaired, but which is not reached by all ALK 
gain-of-function mutations reported thus far. Animal models are not yet available but knock-
in mice bearing mutations at codon p.F1174 and p.R1245 are being generated in several 
groups. In the CNS of mice, Alk is expressed in several thalamic and hypothalamic nuclei, the 
pons, the medulla oblongata and the ventral horn of the spinal cord [Vernersson et al., 2006]. 
It will be of high interest to explore the consequences of endogenous expression of mutant 
ALK on both neurological function and anatomic development of the pons, medulla and 
motor neurons.  
 
There is a growing list of genes for which somatic and germline gain-of-function 
mutations have been reported in tumours (of various types) and syndromes respectively 
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(Table 1). Interestingly, tumour predisposition burdens a minority of these syndromes. The 
repertoire of mutations and the relative proportion of each nucleotidic variation (and amino 
acid substitution) are different between somatic and germline cases. As a general rule, 
mutations exhibiting the highest activating effect in vitro are prevalent in the somatic 
repertoire and absent from its germline counterpart. The HRAS gene stands as a paradigm. 
Somatic gain-of-function mutations at codons p.G12, p.G13 and p.Q61 are found in various 
tumours, whereas germline mutations at codon p.Q61 have not been reported in patients with 
Costello syndrome. Moreover, when considering amino acid changes at codon 12, p.G12V is 
far more frequent somatically than p.G12S (and leading to a greater activation [Fasano, et al., 
1984]), while in Costello syndrome p.G12S is the most common substitution, with p.G12V 
having been reported only twice; both of these patients had a severe phenotype [van der 
Burgt, et al., 2007]. Most interestingly, two “missing germline mutations” at codon 61 (Q61R 
and Q61K) of HRAS have been identified in 5/30 spermatocytic seminomas (a rare testicular 
germ cell tumour of late-age onset) [Goriely, et al., 2009]. We thus speculate that such 
mutations are to be found in the germline but probably lead to an extreme, possibly foetal 
lethal phenotype, distinct from Costello syndrome. 
Here we report a novel syndrome with predisposition to NB due to constitutive ALK 
gain-of-function mutations. In doing so, we provide evidence that normal CNS development 
requires regulation of ALK activity, with a threshold being exceeded for some mutations 
only, and therefore we add ALK to the list of oncogenes with important roles in normal 
development.   
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Table and Figures 
Figure 1: Brain MRI of the two patients and three controls. 
Note the abnormal shape of the brainstem with enlarged medulla oblongata eclipsing the 
ovoid form of the pons (arrows) on brain MRI (T1-weighted sagittal images) in both cases 
(top) as compared to controls (bottom, arrowheads). 
A) patient 1, B) patient 2, C) antenatal MRI of a control foetus at 34 weeks gestation, D-E) 
controls.   
 
Figure 2: ALK gene mutations. 
2A. A constitutional heterozygous missense variation of the ALK gene having occurred de 
novo was identified in each case (c.3733T>G, p.F1245V in case 1 and c.3520T>G, p.F1174V 
in case 2, with numbering based on the cDNA sequence from NM_004304.3 (ALK_v001). 
There are no evidence that the ALK mutations are present in mosaic state. Indeed mutant 
allele is not under-represented compared to wild-type allele. Residue F1245 is located in the 
catalytic loop and residue F1174 in the C helix of the TKD [Bossi, et al., 2010; Lee, et al., 
2010]. 
2B. Published ALK mutations in NB (adapted from (Janoueix-Lerosey, et al., 2010) with 
permission). Mutations are indicated by arrows, with the number of mutations identified at 
each position to date indicated underneath. The mutations are mainly located in the TK 
domain, with two hotspots at positions 1174 and 1275. 
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Gene MIM 
Somatic mutation /  
tumour predisposition 
Germline mutation /  
Syndromes Reference 
RET 164761 Thyroid  MEN2A / MEN2B* [Mulligan, et al., 1993; Hofstra, et al., 1994] 
FGFR3 134934 Bladder / Skin / Haematopoietic Achondroplasia / TD [Rousseau, et al., 1994] 
FGFR2 176943 Uterus / Skin / Testicle Crouzon / Apert / Pfeiffer [Reardon, et al., 1994; Wilkie, et al., 1995] 
HRAS 190020 Bladder / Thyroid / Skin Costello* [Aoki, et al., 2005] 
KRAS 190070 Colon / Pancreas / Lung Noonan / CFC [Niihori, et al., 2006] 
BRAF 164757 Colon / Thyroid / Skin CFC [Niihori, et al., 2006] 
PTPN11 176876 Haematopoietic Noonan [Tartaglia, et al., 2001] 
IDH2 147650 CNS / Haematopoietic D2 Hydroxyglutaric Aciduria [Kranendijk, et al.] 
ALK 105590 PNS Congenital encephalopathy  this report 
 
Table 1: List of genes for which somatic and germline gain-of-function mutations have been reported in tumours and syndromes 
respectively. 
Syndromes predisposing to tumours are indicated with an asterisk. Several cases of leukemia have been reported in CFC. A paternal age effect is 
observed for germline mutations of RET, FGFR2, FGFR3, HRAS and PTPN11.  
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